查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2081570

外陰疼痛治療市場：2026-2032年全球市場預測（依治療方法、給藥途徑、處方狀態、治療階段、治療持續時間及通路分類）

Vulvodynia Treatment Market by Treatment Type, Route Of Administration, Prescription Status, Line Of Therapy, Duration, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，治療外陰部疼痛的市場規模將成長至 32.8 億美元，複合年成長率為 6.39%。

主要市場統計數據
基準年 2025 21.2億美元
預計年份：2026年 22.5億美元
預測年份 2032 32.8億美元
複合年成長率 (%) 6.39%

外陰疼痛的治療正從單純的症狀治療轉向以實證醫學為基礎的多學科綜合治療，尤其針對持續至少三個月且病因不明的慢性外陰疼痛。同行評審的流行病學研究表明，外陰疼痛影響相當比例的育齡婦女和停經後婦女，終生盛行率通常估計在個位數到十幾例之間。然而，由於其症狀與感染疾病、皮膚疾病、骨盆底功能障礙、閉經相關的泌尿生殖系統綜合症以及神經病變疼痛的症狀重疊，因此診斷往往會延遲。

醫療保健專業人員、保險公司和生命科學公司面臨的機會在於改善早期檢測、建立分層治療方案以及評估長期療效。高品質的外陰疼痛治療日益融合了患者教育、外陰疼痛護膚、骨盆底物理治療、性心理和性功能諮詢、認知行為療法、局部治療、神經病變疼痛藥物、必要時的荷爾蒙療法以及針對特定局部誘發前庭疼痛病例的治療方案。

外陰疼痛治療前景的變革性變化

人們日益認知到，慢性骨盆疼痛並非單一器官疾病，而是一種生物心理社會疾病，因此，外陰疼痛的治療方法正在被重新定義。臨床指引越來越強調排除可識別病因、使用檢驗的疼痛和性功能評估量表、評估骨盆底肌肉受累情況以及在保守治療無效時將患者轉診至骨盆底物理治療或疼痛專科的重要性。

人工智慧對治療外陰疼痛的累積影響

人工智慧 (AI) 可以透過促進早期檢測、風險分層和臨床決策支持，改善外陰疼痛的治療，從而打破分散的診療路徑。利用自然語言處理技術，可以從電子健康記錄病歷中識別出反覆出現的症狀模式，例如慢性灼痛、誘發竇部疼痛、反覆傳染病檢查結果為陰性、性交疼痛、盆底壓痛、外陰疼痛以及反覆抗真菌藥物。

外陰疼痛治療市場的關鍵區域洞察

北美在女性外陰疼痛治療意識、婦科專科、骨盆腔疼痛診所、骨盆底物理治療以及女性健康數位化醫療應用方面仍發揮著重要作用。美國引領大部分創新，而加拿大則受益於以指南為基礎的基層醫療和公共醫療服務。在歐洲，尤其是在英國、德國、法國、義大利和西班牙，擁有強大的多學科診療體系，涵蓋婦科、泌尿系統、泌尿科、物理治療、疼痛醫學和性心理醫學等領域，但報銷、轉診途徑和等待時間因醫療體系的不同而存在很大差異。

針對外陰疼痛治療啟動的關鍵群體特定發現。

在東協地區，都市區醫療保健投資的增加、智慧型手機的廣泛普及以及遠端醫療的採用，有望改善婦科護理、性健康諮詢和骨盆底康復服務的可及性。然而，文化障礙往往抑制了女性對陰部疼痛和性交疼痛的訴求。在海灣合作理事會（GCC）市場，醫院的現代化、私人專科醫療機構的發展以及醫療旅遊基礎設施的完善，有望提供高品質的女性醫療保健服務。同時，歐盟的優勢在於其跨境臨床研究能力、統一的醫療設備法規、資料保護標準以及多學科疼痛管理實踐。

主要國家外陰疼痛治療趨勢

美國是外陰疼痛治療領域創新最活躍的國家，這得益於許多專業的骨盆腔疼痛中心、女性健康新創公司、骨盆底治療網路以及病患權益倡導組織。在加拿大，基層醫療轉診模式和公共資助的專科醫療服務正推動著該領域的穩定發展。同時，由於都市區私立醫療保健的發展、婦科保健意識的提高以及遠端醫療帶來的專家諮詢服務管道的拓展，墨西哥和巴西的外陰疼痛治療需求尚未得到充分滿足。

為行業領導者提供的實用建議

由於外陰疼痛的診斷率仍然很低，在被確診為慢性疼痛之前，往往被誤診為複發性性行為感染，因此，行業供應商應優先考慮以「教育優先」的方式進行市場開發。具體措施包括：培訓婦產科醫生和基層醫療醫生進行鑑別診斷；與骨盆底物理治療師建立轉診網路；整合行為健康和性諮詢服務；以及利用檢驗的患者報告結局（PRO）來證明其臨床價值。

了解外陰疼痛治療方法的調查方法

本執行摘要基於系統的二手研究途徑，涵蓋同行評審的臨床文獻、婦科和疼痛指南、公共衛生資訊來源、法律規範、保險報銷趨勢以及醫療服務趨勢。研究結果從多個角度檢驗，包括流行病學、診斷標準、臨床實踐、數位醫療應用、當地醫療基礎設施和治療活用狀況。

結論：外陰疼痛治療的未來

隨著臨床醫生、保險公司和創新者逐漸認知到慢性外陰陰道疼痛對性健康、心理健康、人際關係和日常生活功能造成的負擔，外陰陰道疼痛的治療正進入一個更系統化的階段。這系統並非由單一療法構成，而是能夠在婦科、骨盆底復健、疼痛醫學、皮膚科、心理學和性學等領域提供協作、個人化和以結果為導向的照護。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：外陰疼痛治療市場：依治療類型分類

  • 非藥物治療
    • 物理治療
    • 心理治療
    • 神經調控療法/使用設備進行治療
  • 藥物治療
    • 局部治療
    • 口服藥物
    • 荷爾蒙療法

第8章：外陰疼痛治療市場：依給藥途徑分類

  • 外用
  • 口服
  • 注射藥物

第9章：外陰疼痛治療市場：依處方狀態分類

  • 處方
  • 非處方藥

第10章：外陰疼痛治療市場：依治療階段分類

  • 一線治療
  • 第二行
  • 第三行
  • 難治性病例的護理

第11章：外陰疼痛治療市場：依時期分類

  • 短期治療
  • 長期治療

第12章：外陰疼痛治療市場：依通路分類

  • 醫院藥房
  • 零售藥房
  • 網路藥房

第13章：外陰疼痛治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章：外陰疼痛治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 外陰疼痛治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Amgen Inc.
  • Bayer AG
  • BioMoi LLC
  • Cipla Limited
  • Desert Harvest
  • Good Clean Love
  • Initiator Pharma A/S
  • MAC Research Limited
  • Merck & Co., Inc.
  • NeuEve LLC
  • Novartis AG
  • Peptonic Medical AB
  • Sanofi SA
  • Solis Pelvic Health, LLC
  • Soul Source
  • SPM Therapeutics Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • VuVatech, LLC
  • YoniFlex
Product Code: MRR-433BAD49EE73

The Vulvodynia Treatment Market is projected to grow by USD 3.28 billion at a CAGR of 6.39% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.12 billion
Estimated Year [2026] USD 2.25 billion
Forecast Year [2032] USD 3.28 billion
CAGR (%) 6.39%

Vulvodynia treatment is moving from a narrowly symptomatic approach toward multidisciplinary, evidence-informed care for chronic vulvar pain lasting at least three months without a clearly identifiable cause. Peer-reviewed epidemiology has shown that vulvodynia affects a meaningful share of women across reproductive and postmenopausal ages, with lifetime prevalence estimates commonly cited in the high single digits to mid-teens, yet diagnosis remains delayed because symptoms overlap with infections, dermatologic disease, pelvic floor dysfunction, genitourinary syndrome of menopause, and neuropathic pain.

For healthcare providers, payers, and life sciences organizations, the opportunity lies in improving earlier recognition, stratified treatment pathways, and longitudinal outcomes measurement. High-value vulvodynia care increasingly combines patient education, vulvar skin care, pelvic floor physical therapy, psychosexual counseling, cognitive behavioral therapy, topical therapies, neuropathic pain agents, hormonal treatment when indicated, and procedural options for selected localized provoked vestibulodynia cases.

Transformative Shifts in the Vulvodynia Care Landscape

The vulvodynia treatment landscape is being reshaped by stronger recognition of chronic pelvic pain as a biopsychosocial condition rather than a single-organ disorder. Clinical guidance increasingly emphasizes ruling out identifiable causes, using validated pain and sexual function measures, assessing pelvic floor muscle involvement, and referring patients to pelvic floor physical therapy or pain specialists when conservative care is insufficient.

Another major shift is the expansion of women's health investment beyond fertility and contraception into chronic gynecologic pain, sexual wellness, menopause care, and digital therapeutics. This creates demand for clinician education, standardized diagnostic workflows, non-opioid pain management, integrated behavioral health, and patient-centered care models that address quality of life, dyspareunia, anxiety, depression, sleep disruption, and relationship impact.

Cumulative Impact of Artificial Intelligence on Vulvodynia Treatment

Artificial intelligence can improve vulvodynia care by supporting earlier detection, risk stratification, and clinical decision support across fragmented care pathways. Natural language processing can help identify recurring symptom patterns in electronic health records, such as chronic burning, provoked vestibular pain, recurrent negative infection testing, dyspareunia, pelvic floor tenderness, vulvar allodynia, and repeated empiric antifungal use.

AI also has potential in virtual triage, patient-reported outcome tracking, pelvic floor rehabilitation adherence, and real-world evidence generation. However, clinical adoption must be governed by privacy safeguards, bias testing, transparent validation, and clinician oversight because vulvar pain is underreported, culturally sensitive, and often misclassified in structured health data.

Key Regional Insights Across Vulvodynia Treatment Markets

North America remains highly influential in vulvodynia treatment awareness, specialty gynecology, pelvic pain clinics, pelvic floor physical therapy access, and women's health digital care adoption, with the United States driving much of the innovation and Canada benefiting from guideline-based primary care and publicly funded health services. Europe shows strong multidisciplinary care capacity through gynecology, dermatology, urology, physiotherapy, pain medicine, and psychosexual medicine, particularly in the United Kingdom, Germany, France, Italy, and Spain, while reimbursement, referral pathways, and waiting times vary widely across health systems.

Asia-Pacific is gaining momentum as women's health awareness, urban specialty care, and telehealth expand in China, India, Japan, Australia, and South Korea; Australia is especially notable for pelvic health physiotherapy integration, while Japan and South Korea benefit from advanced diagnostics and structured specialist care. Latin America, the Middle East, and Africa remain underpenetrated because of specialist shortages, stigma around sexual pain, uneven access to pelvic floor rehabilitation, and limited chronic pelvic pain coding, but these regions present long-term care-improvement potential through clinician training, culturally appropriate education, telemedicine, and integration with reproductive health and menopause services.

Key Group Insights for Vulvodynia Treatment Adoption

Within ASEAN, rising urban healthcare investment, broader smartphone access, and telemedicine adoption can improve access to gynecology, sexual health counseling, and pelvic rehabilitation, although cultural barriers often suppress reporting of vulvar pain and dyspareunia. GCC markets are positioned for premium women's health services through hospital modernization, private specialty care, and medical tourism infrastructure, while the European Union benefits from cross-border clinical research capacity, harmonized medical device regulation, data protection standards, and multidisciplinary pain management practices.

BRICS economies represent a large unmet-need base due to population scale, growing middle-class healthcare spending, and expanding digital health infrastructure, particularly in Brazil, India, China, and South Africa, though access remains uneven between metropolitan and rural settings. G7 countries remain the most commercially mature because of specialty care density, reimbursement capacity, research output, and patient advocacy visibility, while NATO member markets overlap strongly with advanced healthcare systems where chronic pelvic pain pathways, non-opioid pain strategies, and women's health service integration are increasingly formalized.

Key Country Insights in Vulvodynia Treatment

The United States is the most active environment for vulvodynia treatment innovation, supported by specialty pelvic pain centers, women's health startups, pelvic floor therapy networks, and high patient advocacy visibility. Canada shows steady adoption through primary care referral models and publicly funded specialty services, while Mexico and Brazil present unmet demand driven by urban private care growth, improving gynecologic awareness, and expanding access to telehealth-enabled specialist consultation.

In Europe, the United Kingdom, Germany, France, Italy, and Spain benefit from strong clinical expertise in gynecology, dermatology, pain care, physiotherapy, and psychosexual medicine, but face variable wait times, reimbursement pathways, and regional service availability; Russia has specialist capacity in major cities but uneven access across regions. China and India offer scale and rapid digital health adoption, Japan and South Korea bring advanced diagnostics and conservative care models, and Australia stands out for pelvic health physiotherapy integration, chronic pain literacy, and public awareness of women's pelvic health conditions.

Actionable Recommendations for Industry Leaders

Industry vendors should prioritize education-first market development because vulvodynia remains underdiagnosed and frequently treated as a recurrent infection before chronic pain is recognized. Practical actions include training gynecologists and primary care clinicians on differential diagnosis, building referral networks with pelvic floor physical therapists, integrating behavioral health and sexual counseling, and using validated patient-reported outcomes to demonstrate clinical value.

Organizations should invest in non-opioid multimodal care, evidence generation, and culturally sensitive patient engagement. The strongest strategies will combine clinical credibility, reimbursement evidence, real-world outcomes, digital adherence support, and partnerships with women's health clinics, pain centers, academic researchers, professional associations, and patient advocacy organizations.

Research Methodology for Vulvodynia Treatment Insights

The executive summary is based on a structured secondary research approach covering peer-reviewed clinical literature, gynecology and pain guidance, public health sources, regulatory frameworks, reimbursement patterns, and healthcare delivery trends. Insights were triangulated across epidemiology, diagnostic criteria, clinical practice, digital health adoption, regional care infrastructure, and treatment modality utilization.

The methodology emphasizes verified information over speculative claims. Market interpretation focuses on observable indicators such as prevalence ranges in published studies, recognized diagnostic criteria, therapy availability, specialist access, telehealth adoption, pelvic floor rehabilitation capacity, clinical guideline alignment, patient advocacy activity, and the maturity of women's health investment ecosystems.

Conclusion: The Future of Vulvodynia Treatment

Vulvodynia treatment is entering a more structured phase as clinicians, payers, and innovators recognize the burden of chronic vulvar pain on sexual health, mental health, relationships, and daily function. The ecosystem is not defined by a single therapy but by the ability to deliver coordinated, individualized, and outcomes-based care across gynecology, pelvic floor rehabilitation, pain medicine, dermatology, psychology, and sexual medicine.

Sustainable progress will depend on earlier diagnosis, stronger referral pathways, validated outcomes, patient education, and responsible use of digital and AI-enabled tools. Organizations that address underdiagnosis, reduce stigma, and build trusted multidisciplinary solutions will be best positioned in the evolving vulvodynia treatment ecosystem.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Vulvodynia Treatment Market, by Treatment Type

  • 7.1. Non-Pharmacological Treatment
    • 7.1.1. Physical Therapy
    • 7.1.2. Psychological Therapy
    • 7.1.3. Neuromodulation / Device-Based Therapy
  • 7.2. Pharmacological Treatment
    • 7.2.1. Topical Treatments
    • 7.2.2. Oral Medications
    • 7.2.3. Hormonal Therapies

8. Vulvodynia Treatment Market, by Route Of Administration

  • 8.1. Topical
  • 8.2. Oral
  • 8.3. Injectable

9. Vulvodynia Treatment Market, by Prescription Status

  • 9.1. Prescription
  • 9.2. Over-The-Counter

10. Vulvodynia Treatment Market, by Line Of Therapy

  • 10.1. First-Line
  • 10.2. Second-Line
  • 10.3. Third-Line
  • 10.4. Refractory Care

11. Vulvodynia Treatment Market, by Duration

  • 11.1. Short-Term Therapy
  • 11.2. Long-Term Therapy

12. Vulvodynia Treatment Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Retail Pharmacies
  • 12.3. Online Pharmacies

13. Vulvodynia Treatment Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Vulvodynia Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Vulvodynia Treatment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Amgen Inc.
  • 17.2. Bayer AG
  • 17.3. BioMoi LLC
  • 17.4. Cipla Limited
  • 17.5. Desert Harvest
  • 17.6. Good Clean Love
  • 17.7. Initiator Pharma A/S
  • 17.8. MAC Research Limited
  • 17.9. Merck & Co., Inc.
  • 17.10. NeuEve LLC
  • 17.11. Novartis AG
  • 17.12. Peptonic Medical AB
  • 17.13. Sanofi S.A.
  • 17.14. Solis Pelvic Health, LLC
  • 17.15. Soul Source
  • 17.16. SPM Therapeutics Inc.
  • 17.17. Takeda Pharmaceutical Company Limited
  • 17.18. Teva Pharmaceutical Industries Ltd.
  • 17.19. VuVatech, LLC
  • 17.20. YoniFlex

LIST OF FIGURES

  • FIGURE 1. GLOBAL VULVODYNIA TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL VULVODYNIA TREATMENT MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL VULVODYNIA TREATMENT MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL VULVODYNIA TREATMENT MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL VULVODYNIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL VULVODYNIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NON-PHARMACOLOGICAL TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NON-PHARMACOLOGICAL TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NON-PHARMACOLOGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PHYSICAL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PHYSICAL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PHYSICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PSYCHOLOGICAL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PSYCHOLOGICAL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PSYCHOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NEUROMODULATION / DEVICE-BASED THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEUROMODULATION / DEVICE-BASED THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NEUROMODULATION / DEVICE-BASED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PHARMACOLOGICAL TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PHARMACOLOGICAL TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PHARMACOLOGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TOPICAL TREATMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TOPICAL TREATMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TOPICAL TREATMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ORAL MEDICATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ORAL MEDICATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ORAL MEDICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HORMONAL THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HORMONAL THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HORMONAL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PRESCRIPTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PRESCRIPTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PRESCRIPTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL OVER-THE-COUNTER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL OVER-THE-COUNTER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL OVER-THE-COUNTER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL FIRST-LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL FIRST-LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL FIRST-LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SECOND-LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SECOND-LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SECOND-LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL THIRD-LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL THIRD-LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL THIRD-LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL REFRACTORY CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL REFRACTORY CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL REFRACTORY CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SHORT-TERM THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SHORT-TERM THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SHORT-TERM THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL LONG-TERM THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL LONG-TERM THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL LONG-TERM THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC VULVODYNIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA VULVODYNIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA VULVODYNIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE VULVODYNIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST VULVODYNIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA VULVODYNIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN VULVODYNIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. GCC VULVODYNIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. GCC VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. GCC VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 142. GCC VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 143. GCC VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 144. GCC VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 145. GCC VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 146. GCC VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 147. GCC VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION VULVODYNIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS VULVODYNIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. G7 VULVODYNIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 167. G7 VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. G7 VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 169. G7 VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 170. G7 VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 171. G7 VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 172. G7 VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 173. G7 VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 174. G7 VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 175. NATO VULVODYNIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 176. NATO VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. NATO VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 178. NATO VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 179. NATO VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 180. NATO VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 181. NATO VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 182. NATO VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 183. NATO VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES VULVODYNIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED STATES VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. CANADA VULVODYNIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 195. CANADA VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. CANADA VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 197. CANADA VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 198. CANADA VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 199. CANADA VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 200. CANADA VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 201. CANADA VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 202. CANADA VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 203. MEXICO VULVODYNIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 204. MEXICO VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. MEXICO VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 206. MEXICO VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 207. MEXICO VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 208. MEXICO VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 209. MEXICO VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 210. MEXICO VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 211. MEXICO VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 212. BRAZIL VULVODYNIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 213. BRAZIL VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. BRAZIL VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 215. BRAZIL VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 216. BRAZIL VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 217. BRAZIL VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 218. BRAZIL VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 219. BRAZIL VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 220. BRAZIL VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED KINGDOM VULVODYNIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED KINGDOM VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED KINGDOM VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED KINGDOM VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED KINGDOM VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED KINGDOM VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED KINGDOM VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED KINGDOM VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED KINGDOM VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 230. GERMANY VULVODYNIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 231. GERMANY VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. GERMANY VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 233. GERMANY VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 234. GERMANY VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 235. GERMANY VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 236. GERMANY VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 237. GERMANY VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 238. GERMANY VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. FRANCE VULVODYNIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 240. FRANCE VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. FRANCE VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 242. FRANCE VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 243. FRANCE VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 244. FRANCE VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 245. FRANCE VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 246. FRANCE VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 247. FRANCE VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 248. RUSSIA VULVODYNIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 249. RUSSIA VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. RUSSIA VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 251. RUSSIA VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 252. RUSSIA VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 253. RUSSIA VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 254. RUSSIA VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 255. RUSSIA VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 256. RUSSIA VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 257. ITALY VULVODYNIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 258. ITALY VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. ITALY VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 260. ITALY VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 261. ITALY VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 262. ITALY VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 263. ITALY VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 264. ITALY VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 265. ITALY VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 266. SPAIN VULVODYNIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 267. SPAIN VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. SPAIN VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 269. SPAIN VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 270. SPAIN VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 271. SPAIN VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 272. SPAIN VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 273. SPAIN VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 274. SPAIN VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA VULVODYNIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 278. CHINA VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 284. INDIA VULVODYNIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 285. INDIA VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. INDIA VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 287. INDIA VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 288. INDIA VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 289. INDIA VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 290. INDIA VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 291. INDIA VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 292. INDIA VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 293. JAPAN VULVODYNIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 294. JAPAN VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 295. JAPAN VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 296. JAPAN VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 297. JAPAN VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 298. JAPAN VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 299. JAPAN VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 300. JAPAN VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 301. JAPAN VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 302. AUSTRALIA VULVODYNIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 303. AUSTRALIA VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 304. AUSTRALIA VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 305. AUSTRALIA VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 306. AUSTRALIA VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 307. AUSTRALIA VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 308. AUSTRALIA VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 309. AUSTRALIA VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 310. AUSTRALIA VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 311. SOUTH KOREA VULVODYNIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 312. SOUTH KOREA VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 313. SOUTH KOREA VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 314. SOUTH KOREA VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 315. SOUTH KOREA VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 316. SOUTH KOREA VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 317. SOUTH KOREA VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 318. SOUTH KOREA VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 319. SOUTH KOREA VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)